Private equity majors Cinven and Bain Capital have agreed to buy microbial control chemical specialist Lonza Specialty Ingredients in a CHF4.2bn ($4.7bn) deal.
Private equity majors Cinven and Bain Capital have agreed to buy microbial control chemical specialist Lonza Specialty Ingredients in a CHF4.2bn ($4.7bn) deal.